ClearOne dispatches definitive merger information statement, triggering 20-day countdown for Cortigent deal
CLRO has more than doubled off its 52-week low of $2.71.
Summary
With the definitive merger proxy now mailed, the 20-day clock begins for ClearOne's reverse merger with Cortigent. The transaction will hand 78% control to Vivani and massively dilute existing shareholders, while a concurrent discounted financing aims to fund the combined neurotech company.
Key Events · M&A and Partnerships · CLRO
-
Definitive Merger Proxy Filed
ClearOne has mailed the definitive Schedule 14C for its merger with Cortigent, initiating the 20-day waiting period required before the deal can close. Majority written consent approved the merger on August 3, 2026.
-
Extreme Dilution for Existing Holders
Post-merger, existing ClearOne shareholders will own only 16.7% of the combined company. Vivani Medical will receive 12.5M shares for a 78% stake, and advisors will get 855K shares representing 5.3%, based on 2.68M shares currently outstanding.
-
Concurrent Financing at Deep Discount
The deal is conditioned on a $10M–$15M unit offering priced at $3.50 per unit—a 54% discount to ClearOne's $7.65 stock price. Each unit includes one share and one $10 warrant, implying potential further dilution if warrants are exercised.
-
Cortigent Financials Reveal Distress
Included financials show Cortigent is pre-revenue with a going-concern warning, $428K in cash, and a $3.8M working capital deficit as of March 31, 2026. It lost $3.1M in 2025 and relies on Vivani for funding.
Analysis · CLRO · Manufacturing
The definitive information statement for ClearOne's reverse merger with neurotech developer Cortigent has been mailed, starting the 20-day SEC waiting period before the transaction can close. Included financials reveal that Cortigent is pre-revenue, carries a going-concern warning, and the deal is paired with a concurrent $10M–$15M financing priced at $3.50 per unit—a steep discount to ClearOne's $7.65 stock price. Existing shareholders face extreme dilution, retaining just 16.7% of the combined company post-merger, while Vivani will control 78%. The arrangement offers a lifeline to both firms but imposes a heavy cost on current holders.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 47.7% of the 235 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLRO was trading at $7.65 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $24M. The 52-week trading range was $2.71 to $16.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.